Who is PReMA ? Does PReMA sell medicine? Is it a private or government organization?
PReMA (Pharmaceutical Research and Manufacturers Association) is not a company that sells medicine but we are a private non-profit association. Currently, PReMA represents 38 members who are research-based pharmaceutical companies which aim to research and develop innovative medicines to combat with the incurable diseases or improve the existing treatment to be more efficient.
When was PReMA established?
PReMA was established since 1970 but its name was PPA (Pharmaceutical Products Association). Later its name was changed to PPA - (Pharmaceutical Producers Association) and finally it’s been changed to PReMA as in the present.
What is the objective of establishing PReMA?
The Pharmaceutical Research and Manufacturers Association (PReMA) is dedicated to promoting good health and quality of life for the Thai people and to support the advancement of public health systems through the research and development of innovative medicines. PReMA also supports the rights to choice by the people and the healthcare professionals to high quality medicines that best meet their needs.
PReMA is the non-profit organization, then where do its budgets come from?
PReMA has no product to sell in the market. Therefore, our budgets that we use to conduct the activities come from the annual member fee.
What is the benefit as the member of PReMA?
PreMA member will receive many benefits such as able to receive inside industry dynamic information such as monthly sales exchange, survey on compensation and benefits, news clipping, participate in new initiatives such as Sales Rep accreditation and participate in various subcommittees to shape the association policy
What does PReMA do for the society?
PReMA’s main roles consist of: promoting healthier lives through scientific advancements in research and development of high quality medicines by its members; encourage compliance with ethical international standards; collaborate to support patients’ timely access to innovative medicines; educate and train related parties in public health systems, and promote understanding of the benefits of intellectual property rights in the development of innovative medicines. All of which align with PReMA’s value of “Innovative Medicines. Healthier Life”
Why are all members of PReMA the foreign companies? Can Thai companies join PReMA?
PReMA does not have the rule about the nationality of member company, but the member has to be the pharmaceutical company that emphasize on research and development of an innovative or original medicine. Therefore, If any Thai company is the research-based one, they can join PReMA and PReMA hopes that we can collaborate to create the innovative medicine for the healthier life Thai people. In addition, though most PReMA member is the foreign company, 99% of their employees are Thai people.
Why do PReMA members have to be research-based pharmaceutical companies?
In the healthcare industry, we found the new emerging or incurable diseases all the time, so PReMA see this important issue and aims to promote the research and development of innovative medicines to deal with those diseases. All we do are for the healthier life of the people.
Is PReMA member of any global association?
PReMA is enlisted in the International Federation of Pharmaceutical Manufacturers Association (IFPMA), which represents worldwide pharmaceutical associations. PReMA is also a member of the World Self-Medication Industry (WSMI), the international voice for self-medication and over-the-counter (OTC) drugs. Moreover, PReMA also has good relations with many medical and pharmaceutical institutions.
What is an original medicine?
Original or Ethical medicine is the medicine that passed many research and development processes. Start with approximately 10,000 compounds to find which one contains the preferred property, then we have to test it with animal to ensure that that it safe enough to use with human. It takes about more than 10 years and huge investment to finish the R&D process and get one efficient medicine to deal with the disease.
What is a generic medicine?
Generic medicine is the medicine that has been produced after the original one had been approved to be the treatment. Generic medicine might copy the formula from the original one, which can reduce the cost of development because there is no research & development by themselves. After the right of the original expires, they can produce the generic one for the easier access from people. However, most important thing is that there must be the good quality control of the production.
Why is the original more expensive than the generic?
Generic medicine has no need to invest in research and development from the beginning which includes complex experiments, drug efficiency study, and clinical trials. All these factors make the generic cheaper than the original. Moreover, the production standard in each company is different, which also affect the price.
Why should Thai people need the intellectual property?
Thailand and international government have regulated the intellectual property law to encourage individual and organizations to have confidence in research and development of innovative product. Because R&D need high investment cost including time to complete the innovation.
These also apply to the pharmaceutical product. The drug research and development spend time more than ten years and high amount of investment. Start from studying more than 10,000 compounds to find the best one or two that can provide the preferred property which also have to test with the animal and human in the latter phase. There are only few drugs that can pass all these processes until become the successful one.
An intellectual property right is created to encourage the investment in research & development in innovative medicine rather than the generic. This right benefits the long term investment to create advancement in treatment and deal with new diseases.
What is the benefit from intellectual property to the people?
People receive enormous benefits from existence of intellectual property law, because this rights will encourage the research and development that can create innovation which will elevate the quality of life. For example, the development of new medicine that can treat the incurable diseases and finding the more effective treatment. If there is no intellectual property, there will be no research and development of new medicine that can save people’s life.
What is CL? What is its effect?
CL stands for Compulsory Licensing which is when a government allows someone else to produce the patented product or process without the consent of the patent owner. It is one of the flexibilities on patent protection included in the WTO’s agreement on intellectual property — the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement. The spirit of the TRIPS Flexibilities is the commitment by all members of the WTO to protect member states’ intellectual property rights whilst being able to accommodate extemporaneous situations as and when required .
Article 31 clearly indicates that “such use may only be permitted if, prior to such use, the proposed user has made efforts to obtain authorization from the right holder on reasonable commercial terms and conditions and that such efforts have not been successful within a reasonable period of time.” In addition, “the right holder shall be paid adequate remuneration in the circumstances of each case, taking into account the economic value of the authorization
CL is a short term measure which can not provide long term benefit to the nation. Using CL is somewhat like breaking the intellectual property law which cause the pharmaceutical companies have no risk compensation to research and develop innovative medicine. All these can result in pharmaceutical companies decide not to import innovative medicine to our country, which we might lose the chance to save many people’s life.
What is the better way to give access to people rather than using CL?
Using CL, people will get only short-term benefits. Therefore, government and private sector should collaborate and find the way to develop the better healthcare system that can give better accessibility to high quality medicine. PReMA is also collaborating with the government sector by creating the p4P program ( Partnership for Patients ) which aims to seek collaboration among public sector, private sector, professionals charity and also the patients.
Where do I find more information about disease and innovative medicines?
You can access the news and knowledge about innovative medicine, healthcare system, diseases and PReMA activities in this website. Moreover, you can find other source of knowledge provided in the links section of the website.